47 Results for "

Temozolomide

" in MedChemExpress (MCE) Product Catalog:
Products (47)

47 Results for "Temozolomide" in MCE Product Catalog:

202
202 Publications Verification
Cat. No.: HY-17364
CAS No.: 85622-93-1
Synonyms: NSC 362856; CCRG 81045; TMZ
Research Areas:  

Cancer

Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-153773
CAS No.: 2361760-87-2
Purity:  99.32%
Target:  

IRE1

Research Areas:  

Cancer

Z4P is a BBB-penetrable IRE1 inhibitor with an IC50 of 1.13 μM. Z4P in combination with Temozolomide (HY-17364) inhibits the growth and recurrence of glioblastoma and has anti-tumor activity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-B0106
CAS No.: 102767-28-2
Synonyms: UCB L059
Target:  

DNA Methyltransferase

Research Areas:  

Neurological Disease Cancer

Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-10261B
CAS No.: 439081-18-2
Purity:  99.98%
Synonyms: (E/Z)-BIBW 2992
Research Areas:  

Others Cancer

(E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-Q66655
CAS No.: 3120494-74-5
YRDC-IN-1 is a blood-brain barrier-permeable YRDC inhibitor. YRDC is a key enzyme that catalyzes the formation of N 6-threonylcarbamoyladenosine at position 37 of tRNA (t 6A37). YRDC-IN-1 selectively inhibits the translation of ANN codon-enriched FABP7, thereby reducing lipid droplet formation, increasing ROS, and reversing the acquired resistance of GBM to Temozolomide (TMZ) (HY-17364). YRDC-IN-1 can be used for the research of glioblastoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-10615
CAS No.: 272769-49-0
Target:  

PARP

Research Areas:  

Cancer

A-620223 is a PARP-1 inhibitor with a Ki of 8 nM against PARP-1 and EC50 of 3 nM in a whole cell assay. A-620223 demonstrates good in vivo efficacy in a B16F10 subcutaneous murine melanoma model in combination with Temozolomide (TMZ) (HY-17364) and in an MX-1 breast xenograph model in combination with Cisplatin (HY-17394). A-620223 can be used for the studies of melanoma and breast cancer .
loading...
    loading...
Cat. No.: HY-B0896
CAS No.: 102-76-1
Synonyms: Glyceryl triacetate; 1,2,3-Triacetoxypropane
Triacetin (Glyceryl triacetate) is a synthetic compound that is a triester of glycerol and acetic acid, orally active. Triacetin increases acetate bioavailability in glioma cells. Triacetin induces glioma cell growth arrest and Apoptosis. Triacetin freely crosses the blood brain barrier/plasma membrane. Triacetin increases histone acetylation and enhances Temozolomide (HY-17364) (TMZ) chemotherapeutic efficacy .
loading...
    loading...
Cat. No.: HY-119696
CAS No.: 3413-72-7
Purity:  99.51%
Target:  

Drug Metabolite

Research Areas:  

Neurological Disease Cancer

MTIC, the active metabolite of Temozolomide (TMZ), is a DNA alkylating agent. MTIC has antitumor activity .
loading...
    loading...
Cat. No.: HY-W018326
CAS No.: 113942-30-6
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

Temozolomide acid is a carboxylic acid derivative of Temozolomide (HY-17364) with anticancer activity. Temozolomide is a DNA alkylating agent, methylating the guanine and adenine bases of DNA, causing breaks in DNA double strand, cell cycle arrest, and eventually cell death. Temozolomide acid is promising for research of glioblastoma and brain cancer .
loading...
    loading...
Cat. No.: HY-136731
CAS No.: 524708-03-0
Purity:  99.52%
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

APE1-IN-1 is a potent and blood-brain barrier (BBB) penetrant apurinic/apyrimidinic (AP) endonuclease 1 (APE1) inhibitor with an IC50 value of 2 μM. APE1-IN-1 can potentiate the cytotoxicity of the alkylating agents Methylmethane sulfonate and Temozolomide (HY-17364) to cancer cells .
loading...
    loading...
Cat. No.: HY-17364S
CAS No.: 208107-14-6
Temozolomide-d3 is the deuterium labeled Temozolomide. Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects .
loading...
    loading...
Cat. No.: HY-149127
CAS No.: 1039760-91-2
Purity:  ≥98.0%
Synonyms: ASC-JM17; ALZ-003
Rosolutamide (ASC-JM17) is an orally active Nrf1/Nrf2 activator. Rosolutamide activates Hsf1 pathways, upregulates proteasome subunits and antioxidant enzymes, induces proteasome complex structural rearrangement, and enhances ubiquitin-proteasome system-mediated degradation. Rosolutamide reduces mutant androgen receptor and ataxin-3 aggregates, restores mitochondrial function, attenuates reactive oxygen species (ROS) levels, induces apoptosis and ferroptosis, and inhibits cancer cell growth. Rosolutamide can be used for the research of spinal and bulbar muscular atrophy, Huntington’s disease, and temozolomide-resistant glioblastoma .
loading...
    loading...
Cat. No.: HY-155888
CAS No.: 3057089-47-8
Purity:  98.41%
Target:  

SWI/SNF Complex

Research Areas:  

Cancer

IV-255 is a selective small molecule inhibitor of the BRG1 bromodomain. IV-255 increases the extent of DNA damage induced by Temozolomide (HY-17364) and Bleomycin (HY-108345). IV-255 inhibits the invasiveness of GBM cells. IV-255 enhances Temozolomide-induced cell death and the apoptosis-inducing activity of Temozolomide .
loading...
    loading...
Cat. No.: HY-B0106R
CAS No.: 102767-28-2
Synonyms: UCB L059 (Standard)
Levetiracetam (Standard) is the analytical standard of Levetiracetam. This product is intended for research and analytical applications. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .
loading...
    loading...
Cat. No.: HY-119993
CAS No.: 510721-85-4
Synonyms: BMH-23
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

AR03 (BMH-23) is an apurinic/apyrimidinic endonuclease 1 (Ape1) inhibitor with an IC50 of 2.1 µM. AR03 has low affinity for double-stranded DNA. AR03 potentiates the cytotoxicity of methyl methanesulfonate and temozolomide in SF767 cells .
loading...
    loading...
Cat. No.: HY-115567
CAS No.: 191421-10-0
Purity:  ≥98.0%
Synonyms: 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole
Target:  

Apoptosis

Research Areas:  

Cancer

5-NIdR (1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole), an artificial nucleoside, exhibits the ability to inhibit the replication of DNA lesions generated by Temozolomide (HY-17364). 5-NIdR induces cancer cells apoptosis and arrests cell cycle at G0 phase. 5-NIdR enhances Temozolomide anti-tumor efficacy in murine glioblastoma model .
loading...
    loading...
Cat. No.: HY-162384
CAS No.: 3034959-68-4
Research Areas:  

Cancer

EPIC-0628 is an inhibitor of the HOTAIR-EZH2 interaction and promotes ATF3 expression. The long noncoding RNA HOTAIR has been found to regulate glioblastoma (GBM) progression and mediate DNA damage repair (DDR) by interacting with the catalytic subunit EZH2 of PRC2. EPIC-0628 also inhibits the ATF3-p38-E2F1 DDR pathway to inhibit the HR pathway and upregulates CDKN1A (p21) expression, causing cell cycle arrest. EPIC-0628 also synergizes with Temozolomide (TMZ) (HY-17364) to enhance its in vivo potency .
loading...
    loading...
Cat. No.: HY-144720
CAS No.: 2616813-99-9
Target:  

SWI/SNF Complex

Research Areas:  

Cancer

BRG1-IN-1 (Compound 11d) is a potent inhibitor of SMARCA4/BRG1. BRG1-IN-1 shows better efficacy than PFI-3 in sensitizing GBM cells to the antiproliferative and cell death inducing effects of Temozolomide in vitro. BRG1-IN-1 enhances the inhibitor effect of Temozolomide on the growth of subcutaneous GBM tumors .
loading...
    loading...
Cat. No.: HY-B0106S
CAS No.: 1133229-29-4
Synonyms: UCB L059-d6
Levetiracetam-d6 is the deuterium labeled Levetiracetam. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .
loading...
    loading...
Cat. No.: HY-17364R
CAS No.: 85622-93-1
Synonyms: NSC 362856 (Standard); CCRG 81045 (Standard); TMZ (Standard)
Temozolomide (Standard) is the analytical standard of Temozolomide. This product is intended for research and analytical applications. Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects .
loading...
    loading...